Intranasal esketamine (Spravato, Janssen) is superior to extended-release quetiapine (Seroquel, AstraZeneca) for treatment-resistant depression, results of a multicenter, head-to-head phase 3 trial show.
A new study confirms the safety and efficacy of the psychedelic MDMA in ethnically and racially diverse populations with moderate to severe post-traumatic stress disorder.
In utero SSRI exposure has been linked to lower brain volume in children. However, more information is needed to understand the significance of this finding.
Academics and researchers in psychiatry and psychopharmacology criticize a review that questions the serotonin hypothesis of depression ― a bedrock principle of depression treatment.